Loading
Palisade Bio, Inc. Stock: price and insider trades · United States
1 insider bought €26k of shares over the last 90 days, the latest filed 05 Oct 2026.
Palisade Bio, Inc.: what insiders have been doing
Palisade Bio, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 27 filings came from 7 insiders.
On the market, 2 insiders bought (10 purchases totalling €260k) while 1 insider sold (1 sale totalling €93k). Purchases outweigh sales by €167k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The buyers include 2 senior executives. Biggest ticket of the year: €93k, sold by Jones Mitchell Lawrence and made public on 8 July 2026 (0.038% of market cap).
The last purchase on record was published on 5 October 2026, which is 13 days ago. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4.
With 27 filings in twelve months, the company is more active than the median of 22 filings across the 5,458 companies we follow on the same exchange. Over the whole record (from 2016), the tally stands at 29 purchases and 2 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists net income at -16.8 m USD.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
78
Thresholds
n/a
Buy Volume
€407,526
29 ops. · all time
Sell Volume
€93,261
2 ops. · all time
Who traded when
BuySaleRobert Baltera Jr.6 buys
Donald Allen Williams4 buys
Mitchell Lawrence Jones1 sale
Since the insiders bought
- -25.4%Entry US$1.89 · Close 16 Oct 2026 US$1.41
- +26.5%Entry US$1.85 · Close at T+90 US$2.34
- -84.7%Entry US$4.51 · Close at T+365 US$0.69
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Palisade Bio, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$9.80.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.41
Analyst consensus
10 analystsStrong buy
US$5.00Target US$9.80(+595%)US$25.00
Income statement
EBITDA-US$16.8M
Net income-US$16.8M0.0% margin
Valuation
PER (trailing)2.4x
PER (forward)-5.0x
P/Book2.0x
Beta1.62
Balance sheet & cash
Market capUS$245.7M
Total debtUS$71k
Free Cash Flow-US$10.8M
Profitability & ownership
ROE-51.4%
ROA-33.0%
% insiders4.2%
% institutions101.4%
Last declaration on 7 October 2026
Declarations78 total
2,620,850 sharesCommon StockSEC:0001493152-26-046202:0
3,227,384 sharesCommon StockSEC:0001493152-26-046201:0
1,031,102 shares@ US$1.490.59% mcap87.9% of flowCommon StockSEC:0001493152-26-046202:1
1,411,982 shares@ US$1.490.81% mcap84.4% of flowCommon StockSEC:0001493152-26-046201:1
10,000 shares@ US$1.420.0056% mcap20.5% of flowCommon StockSEC:0001493152-26-045772:0
Canonical exit: 30 Dec 2026 (T+90)
10,000 shares@ US$1.460.0058% mcap21.3% of flowCommon StockSEC:0001493152-26-045772:1
Canonical exit: 31 Dec 2026 (T+90)
88,400 shares0Common StockSEC:0001493152-26-039746:0
88,400 shares0Common StockSEC:0001493152-26-039746:1
20,000 shares@ US$1.98990.014% mcap15.9% of flowCommon StockSEC:0001493152-26-032884:0
Canonical exit: 6 Oct 2026 (T+90)
25,000 shares@ US$1.9560.017% mcap19.5% of flowCommon StockSEC:0001493152-26-032884:1
Canonical exit: 7 Oct 2026 (T+90)
335,167 sharesCommon StockSEC:0001493152-26-032559:0
131,167 sharesCommon StockSEC:0001493152-26-032561:0
30,000 shares@ US$2.03480.022% mcap24.3% of flowCommon StockSEC:0001493152-26-032563:1
Canonical exit: 5 Oct 2026 (T+90)
133 shares@ US$0.700.0000% mcap0.0% of flowCommon StockSEC:0001493152-26-032559:2
20,000 shares@ US$2.0520.015% mcap16.4% of flowCommon StockSEC:0001493152-26-032563:0
Canonical exit: 4 Oct 2026 (T+90)
51,880 shares@ US$2.05350.038% mcap49.6% of flowCommon StockSEC:0001493152-26-032561:1
53,000 shares@ US$2.040.039% mcap50.4% of flowCommonSEC144:0001974078-26-000267
146,798 shares@ US$2.06640.11% mcap76.3% of flowCommonSEC144:0001974078-26-000266
20,000 shares@ US$1.980.014% mcap15.9% of flowCommon StockSEC:0001493152-26-032229:0
Canonical exit: 29 Sept 2026 (T+90)
10,000 shares@ US$1.980.0071% mcap7.9% of flowCommon StockSEC:0001493152-26-032229:1
Canonical exit: 30 Sept 2026 (T+90)
336,904 sharesCommon StockSEC:0001493152-26-029329:0
592,300 sharesCommon StockSEC:0001493152-26-028570:0
20,200 sharesCommon StockSEC:0001493152-26-028570:1
8,000 sharesCommon StockSEC:0001493152-26-006833:0
13,333 sharesCommon StockSEC:0001493152-26-006831:0
25 of 78 declarations
About Palisade Bio, Inc.
Palisade Bio, Inc. (NASDAQ: PALI) is a clinical-stage biopharmaceutical company headquartered in Carlsbad, California, in the United States and listed on the Nasdaq Capital Market. For investors, the company stands out as a highly focused development story rather than a diversified commercial biotech. Its core strategy is built around a differentiated oral prodrug platform centered on PDE4 biology, with the aim of improving tolerability, pharmacology, and convenience for patients with chronic inflammatory and fibrotic diseases. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001357459/000135745926000004/pali-20251231.htm?utm_source=openai))
The company’s lead asset is PALI-2108, a once-daily oral PDE4 inhibitor prodrug designed to be selectively activated in the terminal ileum and colon. The logic of the program is to concentrate activity at the site of disease while limiting systemic exposure, which may help reduce the class-related CNS and gastrointestinal side effects that have historically constrained PDE4 therapies. Palisade Bio’s disclosed development focus is inflammatory bowel disease, especially ulcerative colitis and fibrostenotic Crohn’s disease, with the platform concept potentially expandable to other inflammatory and fibrotic indications. ([palisadebio.com](https://palisadebio.com/about-us-overview/?utm_source=openai))
Read moreShow less
In competitive terms, Palisade Bio fits the profile of a small-cap U.S. biotech whose valuation is driven primarily by clinical data, regulatory milestones, and funding execution. The company does not yet have a commercial product base or meaningful recurring operating revenue; instead, its investment case depends on whether PALI-2108 can demonstrate a compelling efficacy/safety profile and a clear differentiation versus existing IBD treatments. That makes the shares on the Nasdaq particularly sensitive to trial readouts, protocol updates, and capital raises. ([palisadebio.com](https://palisadebio.com/pipeline-overview/?utm_source=openai))
Recent company updates have been constructive. In 2025 and 2026, Palisade Bio reported positive Phase 1a and Phase 1b results for PALI-2108, including additional topline data in fibrostenotic Crohn’s disease and ulcerative colitis. The latest quarterly update also highlighted continued clinical progress and anticipated Phase 2 trial initiations in 2026, signaling that management is attempting to move the lead program from proof-of-concept into later-stage development. For investors in the United States-listed Nasdaq name, the story remains a classic clinical catalyst pipeline: high upside if execution continues, but also elevated binary risk typical of development-stage biotech. ([palisadebio.com](https://palisadebio.com/palisade-bio-reports-first-quarter-2026-financial-results-and-highlights-continued-clinical-progress-of-pali-2108/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
